Counselors in Pocasset, MA Accepting Medicare
7 Counselors found. Showing 1 - 7
 Baylee Stone, LMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 33 Circuit Ave, Pocasset, MA 02559 Phone: 978-758-6725 |
Maria Cobill Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 830 County Rd, Pocasset, MA 02559 Phone: 508-564-9690 |
Virginia Horvath, M.S. Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 830 County Rd, Pocasset, MA 02559 Phone: 508-564-9690 Fax: 508-564-9699 |
Gloria Elaine Myers-clark, MS Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 830 County Rd, Pocasset, MA 02559 Phone: 508-564-9690 Fax: 508-564-9699 |
 Patrick Mcguire Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 830 County Rd, Pocasset, MA 02559 Phone: 508-564-9690 |
Mr. Gerald Vincent Mckenna, LMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 18 Club House Dr, Pocasset, MA 02559 Phone: 508-314-2983 |
Maureen England, FSS Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 830 County Rd, Pocasset, MA 02559 Phone: 508-564-9690 Fax: 508-564-9699 |
News Archive
Clinical trial planned in Australia and the USA to help patients with ‘orphan' disease
Prana Biotechnology Limited announced today that researchers are planning recruitment for a phase II clinical trial of the experimental drug PBT2 in Huntington's patients. There are currently no treatments for the genetic, neurodegenerative disease; Australia is increasingly seen as a leader in the development of therapies for neurologic disorders. Huntington's often affects young adults and progressively impacts the body, mind and emotions. The disease causes incapacitation and death about 15-25 years after onset.
bioTheranostics' CancerTYPE ID molecular test improves overall survival for patients with CUP
bioTheranostics, developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced study results showing that tumor profiling with its CancerTYPE ID molecular test helped guide site-specific chemotherapy and improve overall survival for patients with carcinoma of unknown primary site.
Review of the health effects of Swedish Snus released
A Ministry of Health-commissioned review of the health effects of Swedish snus aims to inform the debate about whether snus and similar products have a role in reducing tobacco related harm in New Zealand.
Filthy nursing home in Thursday Island – manager fired
The manager looking after an aged care facility in the Torres Strait Islands has been sacked after the nursing home was found filthy and unsuitable for patient care. According to Torres Strait Regional Mayor Fred Gela, the nursing home in question is Star of the Sea on Thursday Island and the incident occurred after the state of affairs was brought to notice by a nurse. He said, "The person that was responsible for the overall administration and overseeing all of that, their employment has been terminated as of Monday."
SwitchGear Genomics, BioCat enter distribution agreement for LightSwitch Luciferase Assay System in Europe
SwitchGear Genomics Inc., a leading provider of products for studying the regulatory elements in the human genome, today announced that the company signed an agreement for BioCat GmbH to distribute the innovative LightSwitch Luciferase Assay System™ in Europe.
› Verified 8 days ago